Payment overview · 2025
General Payments
$240.70
9 reported records · 5 companies
Healthcare provider profile · identity verified
William Michael Carter, MD
Allopathic & Osteopathic Physicians|Family Medicine · TOMPKINSVILLE, KY · NPI 1720013873
Verified facts
What the public records show
CMS Open Payments records show William Michael Carter, MD received $240.70 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 71.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $172.33 | 71.6% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.41 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.00 | 6.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.80 | 6.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.16 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.70 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.96 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 408 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 95 |
| Losartan Potassium | Losartan Potassium | 377 | 86 |
| Gabapentin | Gabapentin | 332 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 324 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 56 |
| Omeprazole | Omeprazole | 232 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 49 |
| Trazodone Hcl | Trazodone Hcl | 209 | 40 |
| Metformin Hcl | Metformin Hcl | 208 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 194 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 189 | 32 |
| Furosemide | Furosemide | 179 | 49 |
| Mirtazapine | Mirtazapine | 178 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 175 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 35 |
| Buspirone Hcl | Buspirone Hcl | 157 | 31 |
| Clonazepam | Clonazepam | 152 | 22 |
| Lisinopril | Lisinopril | 147 | 37 |
| Potassium Chloride | Potassium Chloride | 147 | 41 |
| Atenolol | Atenolol | 140 | 29 |
| Sertraline Hcl | Sertraline Hcl | 140 | 34 |
| Eliquis | Apixaban | 139 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 129 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 36 |
| Levofloxacin | Levofloxacin | 122 | 84 |
| Meloxicam | Meloxicam | 122 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 117 | 28 |
| Azelastine Hcl | Azelastine Hcl | 105 | 64 |
| Ibuprofen | Ibuprofen | 105 | 21 |
| Aripiprazole | Aripiprazole | 104 | 17 |
| Lorazepam | Lorazepam | 99 | 19 |
| Celecoxib | Celecoxib | 98 | 16 |
| Montelukast Sodium | Montelukast Sodium | 97 | 20 |
| Prednisone | Prednisone | 95 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 12 |
| Colchicine | Colchicine | 89 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 22 |
| Alendronate Sodium | Alendronate Sodium | 86 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 13 |
| Spironolactone | Spironolactone | 78 | 20 |
| Ozempic | Semaglutide | 75 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 35 |
| Allopurinol | Allopurinol | 73 | 16 |
| Clonidine Hcl | Clonidine Hcl | 70 | 16 |
| Tramadol Hcl | Tramadol Hcl | 70 | 20 |
| Pregabalin | Pregabalin | 69 | 18 |
| Simvastatin | Simvastatin | 67 | 12 |
| Azithromycin | Azithromycin | 64 | 55 |
| Vraylar | Cariprazine Hcl | 64 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 16 |
| Cephalexin | Cephalexin | 62 | 48 |
| Sucralfate | Sucralfate | 59 | 16 |
| Xarelto | Rivaroxaban | 59 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 15 |
| Methylprednisolone | Methylprednisolone | 58 | 46 |
| Promethazine Hcl | Promethazine Hcl | 54 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 12 |
| Glipizide | Glipizide | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 19 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Fluconazole | Fluconazole | 50 | 30 |
| Naproxen | Naproxen | 50 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 17 |
| Etodolac | Etodolac | 48 | suppressed |
| Estradiol | Estradiol | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 28 |
| Ondansetron Odt | Ondansetron | 43 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 28 |
| Famotidine | Famotidine | 39 | 11 |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 27 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Nystatin | Nystatin | 27 | 19 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.70 · 9 records | ABBVIE INC. | Auvelity, Korlym, QULIPTA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error